Leerink Partnrs Weighs in on Cartesian Therapeutics, Inc.’s FY2027 Earnings (NASDAQ:RNAC)

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) – Equities research analysts at Leerink Partnrs issued their FY2027 EPS estimates for Cartesian Therapeutics in a note issued to investors on Tuesday, April 23rd. Leerink Partnrs analyst T. Smith expects that the company will post earnings of ($7.10) per share for the year. Leerink Partnrs has a “Outperform” rating on the stock. The consensus estimate for Cartesian Therapeutics’ current full-year earnings is ($1.50) per share.

Several other equities research analysts also recently issued reports on RNAC. HC Wainwright boosted their price objective on shares of Cartesian Therapeutics from $2.00 to $54.00 and gave the stock a “buy” rating in a research note on Tuesday. Needham & Company LLC initiated coverage on shares of Cartesian Therapeutics in a research note on Tuesday, April 9th. They set a “buy” rating and a $42.00 price objective for the company. Finally, SVB Leerink initiated coverage on shares of Cartesian Therapeutics in a research note on Tuesday. They set an “outperform” rating and a $39.00 price objective for the company.

Cartesian Therapeutics Stock Up 0.9 %

Cartesian Therapeutics stock opened at $20.90 on Wednesday. Cartesian Therapeutics has a 1 year low of $11.66 and a 1 year high of $42.60. The firm has a 50 day moving average of $19.26.

Cartesian Therapeutics (NASDAQ:RNAC) last released its earnings results on Thursday, March 7th. The company reported ($2.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.30) by ($2.10). Cartesian Therapeutics had a negative net margin of 845.01% and a negative return on equity of 58.21%. The company had revenue of $8.27 million during the quarter.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Cartesian Therapeutics stock. Hall Laurie J Trustee bought a new position in shares of Cartesian Therapeutics, Inc. (NASDAQ:RNAC) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 52,775 shares of the company’s stock, valued at approximately $34,000. Hall Laurie J Trustee owned approximately 0.98% of Cartesian Therapeutics at the end of the most recent quarter. 86.95% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Cartesian Therapeutics

In other news, Director Timothy A. Springer bought 21,612 shares of Cartesian Therapeutics stock in a transaction dated Thursday, March 14th. The shares were acquired at an average cost of $16.20 per share, with a total value of $350,114.40. Following the completion of the transaction, the director now owns 1,017,228 shares in the company, valued at approximately $16,479,093.60. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Over the last three months, insiders have bought 22,472 shares of company stock valued at $365,981. Corporate insiders own 31.20% of the company’s stock.

Cartesian Therapeutics Company Profile

Cartesian Therapeutics, Inc, a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases.